Table 1 Description of populations used in the study
From: Metabolic system alterations in pancreatic cancer patient serum: potential for early detection
Japanese controls | Â |
|---|---|
  All (n) | 50 |
  Female (n) | 20 |
  Male (n) | 30 |
  Age (years, range) | 63.8, 40-75 |
Japanese pancreatic cancer | Â |
  All (n) | 40 |
  Stage I (n) | 4 |
  Stage II (n) | 4 |
  Stage III (n) | 5 |
  Stage IVa (n) | 16 |
  Stage IVb (n) | 11 |
  Collected at surgery1 (n) | 24 |
  Not collected at surgery (n) | 16 |
  Sample collected after treatment2 (n) | 20 |
  Sample collected prior to treatment (n) | 20 |
  Female (n) | 14 |
  Male (n) | 26 |
  Average age (years, range) | 65.2, 31-79 |
USA Caucasian control 1 | Â |
  All ages (n) | 1000 |
  30-39 yrs (n) | 103 |
  40-49 yrs (n) | 280 |
  50-59 yrs (n) | 201 |
  60-69 yrs (n) | 214 |
  70-80 yrs (n) | 202 |
  Female (n) | 598 |
  Male (n) | 402 |
USA Caucasian control 2 | Â |
  All (n) | 40 |
  Female (n) | 8 |
  Male (n) | 21 |
  Gender unknown (n) | 11 |
  Average age (years, range) | 42.7, 18-60 |
USA Caucasian pancreatic cancer | Â |
  All (n) | 14 |
  Female (n) | 3 |
  Gender unknown (n) | 11 |
  Average age (years, range) | 70.4, 57-85 |
USA Caucasian IPMN | Â |
  All, gender unknown (n) | 6 |
  Average age (years, range) | 73.0, 61-80 |